Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
4.550
+0.110 (2.48%)
At close: Nov 3, 2026, 4:00 PM EST
4.580
+0.030 (0.66%)
Pre-market: Nov 4, 2026, 4:05 AM EST
Prime Medicine Employees
Prime Medicine had 146 employees as of December 31, 2025. The number of employees decreased by 68 or 31.78% compared to the previous year. That makes Prime Medicine the 29,011th largest employer in the world and 3,694th in the United States.
Employees
146
Change (1Y)
-68
Growth (1Y)
-31.78%
Revenue / Employee
$27,897
Profits / Employee
-$1,286,932
Market Cap
809.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | -68 | -31.78% |
| Dec 31, 2024 | 214 | -20 | -8.55% |
| Dec 31, 2023 | 234 | 59 | 33.71% |
| Dec 31, 2022 | 175 | 74 | 73.27% |
| Sep 30, 2022 | 150 | 86 | 134.38% |
| Jun 30, 2022 | 137 | 73 | 114.06% |
| Mar 31, 2022 | 101 | - | - |
| Sep 30, 2021 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Alumis | 239 |
| Sana Biotechnology | 142 |
| Annexon | 92 |
| OmniAb | 89 |
| Alto Neuroscience | 68 |
| Corvus Pharmaceuticals | 37 |
| Arbutus Biopharma | 19 |
PRME News
- 19 days ago - Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units - Business Wire
- 4 weeks ago - Prime Medicine doses first patient in PM577a trial - TheFly
- 4 weeks ago - Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewsWire
- 4 weeks ago - Prime Medicine Slides: Corporate presentation - Filings
- 5 weeks ago - Prime Medicine announces FDA clearance of IND application for PM647 - TheFly
- 5 weeks ago - Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 6 weeks ago - Prime Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Prime Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts